jetcityimage/iStock Editorial via Getty Images AmerisourceBergen Drug, now known as Cencora ( NYSE: COR ) awarded an estimated ~$2B modification extending the third two-year six-month option period of a two-year six-month base contract with three two-year six-month option periods for prime vendor pharmaceutical and pharmaceutical-related products and.
Back to Health Page
